Altimmune (ALT) Projected to Post Earnings on Tuesday

Altimmune (NASDAQ:ALT) is projected to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.0020 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Stock Performance

Shares of NASDAQ ALT traded down $0.00 during mid-day trading on Tuesday, hitting $3.00. The stock had a trading volume of 1,306,918 shares, compared to its average volume of 4,312,299. The firm has a market cap of $583.22 million, a PE ratio of -3.22 and a beta of 0.27. The company has a debt-to-equity ratio of 0.12, a quick ratio of 29.56 and a current ratio of 29.56. The company has a 50 day moving average of $2.89 and a two-hundred day moving average of $3.49. Altimmune has a twelve month low of $2.56 and a twelve month high of $6.44.

Institutional Trading of Altimmune

Hedge funds have recently added to or reduced their stakes in the company. Northeast Financial Group Inc. purchased a new position in Altimmune during the fourth quarter worth approximately $48,000. &PARTNERS purchased a new stake in shares of Altimmune in the fourth quarter valued at approximately $54,000. Vontobel Holding Ltd. acquired a new position in shares of Altimmune during the 4th quarter worth approximately $54,000. Martingale Asset Management L P acquired a new position in shares of Altimmune during the 4th quarter worth approximately $52,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Altimmune during the 4th quarter valued at approximately $44,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ALT. Citizens Jmp reduced their price objective on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright restated a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. Leerink Partners assumed coverage on shares of Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price target on the stock. Finally, Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.71.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.